B-MoGen Biotechnologies, Inc. and CytoSen Therapeutics have formed a research collaboration to develop the next generation of gene-modified Natural Killer Cell (NK) therapies.  

B-MoGen will utilize its expertise in genetic design and its patented non-viral gene delivery platform in conjunction with CytoSen’s nanoparticle expansion platform to improve efficacy and reduce cost of NK cell therapeutics. The partnership looks to enable the creation and delivery of new NK cell therapies for cancer patients. 

“We are very excited and look forward to teaming up with CytoSen to utilize our scientific expertise and engineering work with CARs and TCRs to help develop NK treatments in the human therapeutics space,” said Jeff Liter, president and chief executive officer, B-MoGen. “CytoSen’s innovation, science and pioneering technology is a perfect fit with B-MoGen’s genome engineering experience and technology.”

CytoSen’s chief executive officer, Trent Carrier, said, “I am thrilled to see the leveraging of the combined technologies and scientific proficiency of CytoSen and B-MoGen to produce ever more effective NK cell therapeutics. These next generation enhanced NK cells will be put forth in the fight against cancers with the highest unmet medical need.”